Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Q1 2018 Earnings Presentation
18 slides from Precigen's earnings presentation, May 10, 2018
Slide 1: 1Q18 Call May 10, 2018
1Q18 Call May 10, 2018 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the Safe harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are bas
Slide 3: Intrexon's Human Therapeutic Efforts are Now ActoBio Therapeutics & Precigen
Intrexon’s Human Therapeutic Efforts are Now ActoBio Therapeutics & Precigen Bigger payloads, better control improved delivery
Slide 4: ActoBio Therapeutics – Pipeline Update
ActoBio Therapeutics – Pipeline Update ActoBiotics are correctly folded therapeutics synthesized in L. lactis and delivered directly to diseased tissues. Lead program in oral mucositis. Second IND in T1D approved in 1Q18. #1 month follow-up *6 months follow-up
Slide 5: ActoBio Therapeutics: Phase 1/2 Trial in T1D
ActoBio Therapeutics: Phase 1/2 Trial in T1D Ph1 portion of the trial will deliver AG019 (LL-PINS + LL-hIL10) and, if supported by safety data, the Ph2a portion will add low dose anti-CD3 mAb. Each component is predicted to add to efficacy based on clinical and preclinical studies. Trial design base
Slide 6: Precigen / Xogenex – Multigene Expression Solutions for Heart Failure
Precigen / Xogenex – Multigene Expression Solutions for Heart Failure *Xogenex LLC is a majority-owned subsidiary of Precigen; Stats: https://www.cdc.gov/heartdisease/facts.htm, Ambrosy PA et al.; J Am Coll Cardiol. 2014;63:1123–1133 Multigene approach suggested Benefit confirmed in rat model Heart
Slide 7: Updated Scorecard – Human Therapeutics
Updated Scorecard – Human Therapeutics The AG019 IND has cleared and we expect dosing this summer. The trial will initially treat patients with AG019 and expand to Ph2 dosing of AG019 + anti-CD3 if safety allows. The Xogenex Heart Failure trial has started. Plasmid based delivery of the three major
Slide 8: Intrexon's Methane Bioconversion Platform (MBP)
Intrexon’s Methane Bioconversion Platform (MBP) Engineering Microbes for Industrial Applications
Slide 9: Methane Upgrading – A Year Effort
Methane Upgrading – A 90 Year Effort Natural gas is an attractive “feedstock” for the production of liquid fuel and industrial starting materials. Natural gas is the cheapest readily available source of carbon and North America has 100+ years of reserves Natural Gas equates to $18/barrel oil $/barre
Slide 10: Large Markets for Relatively Simple Products
Source: IHS Chemical, ICIS, Markets and Markets, MicroMarket Monitor, Grandview Research, Transparency Market Research Currently limited to $80bn by regulations, IEA World Outlook 2016 data ; IEA World Energy Outlook 2016 data ; Market size for 1-butene and isobutene, the main applications for butyl
Slide 11: Scorecard – Advancing Along a Learning Curve
Development of methanotroph genetic toolbox has accelerated yield improvement Scorecard – Advancing Along a Learning Curve 2,3 BDO yields increased over 25% in Q1 Catalytic conversion of butanediol to butadiene was highly successful Significant progress was made in redesigning the isobutanol “bottle
Slide 12: Oxitec, Trans Ova, Exemplar, Okanagan and AquaBounty
Oxitec: OX5034 Mosquito Exemplar and Trans Ova: MiniSwine and Elite Bovine Embryos Okanagan and AquaBounty: Apple and Salmon
Slide 13: OX5034 is Oxitec's 2nd Generation self-limiting mosquito
OX5034 is Oxitec’s 2nd Generation self-limiting mosquito OX5034 matings with wild-type females yield only viable male offspring This results in no viable biting females but non-biting males survive, passing on the female-lethal gene These male offspring allow the self-limiting gene to persists for u
Slide 14: Friendly Scorecard – Improving Technology, Operations and Focus
Friendly Scorecard – Improving Technology, Operations and Focus OX5034: First field releases for Oxitec’s 2nd generation mosquito are scheduled to launch in Brazil in late May; regulatory approval for field trial granted. Caymans: Preparing to launch “combination” project at request of Cayman govern
Slide 15: Novel MiniSwine Model and Elite Bovine Embryos
Novel MiniSwine Model and Elite Bovine Embryos During the first quarter Trans Ova Genetics launched a new subsidiary called ProGentus. ProGentus will focus on providing products to Dairy and Beef farmers by delivering embryos for the production of replacement females for the farmers’ herd. Exemplar
Slide 16: Arctic Apple – New Product Launch and Orchard Build-out
Arctic® Apple – New Product Launch and Orchard Build-out Arctic® apples 2017 Planted 266,000 Trees 2018 Anticipate planting 600,000+ Trees ApBitz™ snacks launched on Amazon in 1Q18 and quickly became #1 New Release in Dried Fruit within first 24-hrs of sales. Consumer feedback very positive - a prom
Slide 17: AquaBounty Salmon – First U.S. Site Approved
AquaBounty Salmon – First U.S. Site Approved November 19, 2015 – FDA approval for production, sale, and consumption in the U.S. April 27, 2018 – FDA approval to raise AquAdvantage® Salmon at its land-based Indiana facility. AquAdvantage® Salmon awaits only official labeling guidelines by the FDA. Dr
Slide 18: Intrexon
= ac INTREXON’.